Compare PTGX & ASPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | ASPN |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 407.5M |
| IPO Year | 2016 | 2011 |
| Metric | PTGX | ASPN |
|---|---|---|
| Price | $139.08 | $5.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $174.69 | $7.75 |
| AVG Volume (30 Days) | 535.2K | ★ 794.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | N/A | ★ $271,103,000.00 |
| Revenue This Year | $1,078.44 | N/A |
| Revenue Next Year | N/A | $30.02 |
| P/E Ratio | $60.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.24 | $2.30 |
| 52 Week High | $160.81 | $9.35 |
| Indicator | PTGX | ASPN |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 59.02 |
| Support Level | $132.37 | $5.25 |
| Resistance Level | $142.20 | $5.60 |
| Average True Range (ATR) | 4.59 | 0.26 |
| MACD | -0.44 | 0.05 |
| Stochastic Oscillator | 39.61 | 81.48 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.